{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:52:40Z","timestamp":1780987960414,"version":"3.54.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Blood Cancer United","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clml.2026.02.003","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T08:15:15Z","timestamp":1770624915000},"page":"265-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State of the Art Updates and Next Questions | Optimizing Frontline Treatment for Peripheral T-Cell Lymphoma"],"prefix":"10.1016","volume":"26","author":[{"given":"Neha","family":"Akkad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-0670","authenticated-orcid":false,"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2026.02.003_bib0001","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The5th editionof the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2026.02.003_bib0002","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.clml.2016.10.001","article-title":"Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States","volume":"17","author":"Hsi","year":"2017","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2026.02.003_bib0003","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.02.003_bib0004","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1182\/blood-2023-180318","article-title":"Patterns of Care and Impact of Initial Treatment in Peripheral T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort Study","volume":"142","author":"Ruan","year":"2023","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2026.02.003_bib0005","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2023021786","article-title":"A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas","volume":"144","author":"de Leval","year":"2024","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2026.02.003_bib0006","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood.2023021789","article-title":"Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs)","volume":"144","author":"Moskowitz","year":"2024","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.clml.2026.02.003_bib0007","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1200\/JCO.2019.37.15_suppl.7538","article-title":"Response to A+CHP by CD30 expression in the ECHELON-2 trial","volume":"37","author":"Advani","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1016\/j.clml.2026.02.003_bib0008","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1200\/JCO.23.01687","article-title":"Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial","volume":"42","author":"Camus","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.clml.2026.02.003_bib0009","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.18885","article-title":"Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma","volume":"202","author":"Stuver","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.02.003_bib0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2026.02.003_bib0011","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"10168","key":"10.1016\/j.clml.2026.02.003_bib0012","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clml.2026.02.003_bib0013","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.02.003_bib0014","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41408-025-01329-2","article-title":"Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years\u2019 follow-up","volume":"15","author":"Domingo-Dom\u00e8nech","year":"2025","journal-title":"Blood Cancer Journal"},{"issue":"10","key":"10.1016\/j.clml.2026.02.003_bib0015","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"The Oncologist"},{"key":"10.1016\/j.clml.2026.02.003_bib0016","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-136402","article-title":"Trial-in-Progress: Frontline Brentuximab Vedotin and CHP (A+CHP) in Patients with Peripheral T-Cell Lymphoma with Less Than 10% CD30 Expression","volume":"136","author":"Jagadeesh","year":"2020","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.02.003_bib0017","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1200\/JCO.2025.43.16_suppl.7077","article-title":"Frontline brentuximab vedotin (BV) and CHP in patients (pts) with peripheral T-cell lymphoma (PTCL) with <10% CD30 expression: Primary analysis results from the phase 2 SGN35-032 study","volume":"43","author":"Iyer","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"10.1016\/j.clml.2026.02.003_bib0018","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.02.003_bib0019","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.02.003_bib0020","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1016\/S2352-3026(24)00171-6","article-title":"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study","volume":"11","author":"Herrera","year":"2024","journal-title":"The Lancet Haematology"},{"issue":"17","key":"10.1016\/j.clml.2026.02.003_bib0021","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2026.02.003_bib0022","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.clml.2026.02.003_bib0023","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.02.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.63","article-title":"First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation","volume":"6","author":"Wilhelm","year":"2016","journal-title":"Blood Cancer Journal"},{"issue":"19","key":"10.1016\/j.clml.2026.02.003_bib0025","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1182\/bloodadvances.2020003971","article-title":"Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2","volume":"6","author":"Savage","year":"2022","journal-title":"Blood Advances"},{"key":"10.1016\/j.clml.2026.02.003_bib0026","doi-asserted-by":"crossref","unstructured":"Stiff Patrick JM, Unger Joseph R, Cook James S, Constine Louis S, Couban A, Stewart Douglas, et al., Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma. New England Journal of Medicine. 369(18): p. 1681-1690.","DOI":"10.1056\/NEJMoa1301077"},{"issue":"8","key":"10.1016\/j.clml.2026.02.003_bib0027","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1080\/10428194.2018.1563691","article-title":"Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis","volume":"60","author":"Al-Mansour","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1016\/j.clml.2026.02.003_bib0028","first-page":"2646","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.02.003_bib0029","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.clml.2013.07.005","article-title":"A Retrospective Analysis of Peripheral T-Cell Lymphoma Treated With the Intention to Transplant in the First Remission","volume":"13","author":"Mehta","year":"2013","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2026.02.003_bib0030","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clml.2026.02.003_bib0031","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3324\/haematol.2021.279426","article-title":"Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study","volume":"107","author":"Garc\u00eda-Sancho","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2026.02.003_bib0032","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1016\/j.clml.2026.02.003_bib0033","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/jjco\/hyae144","volume":"55","author":"Kita","year":"2025","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.02.003_bib0034","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(24)00102-9","article-title":"Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study","volume":"11","author":"Dupuis","year":"2024","journal-title":"The Lancet Haematology"},{"issue":"18","key":"10.1016\/j.clml.2026.02.003_bib0035","first-page":"2194","article-title":"Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL","volume":"141","author":"Ruan","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.02.003_bib0036","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/bloodadvances.2023011095","article-title":"Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial","volume":"8","author":"Iyer","year":"2024","journal-title":"Blood Advances"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.02.003_bib0037","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-197991","article-title":"Trial in Progress: A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-Cop to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T- Cell Lymphoma - Crescendo","volume":"144","author":"Tiger","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.02.003_bib0038","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","article-title":"Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma","volume":"3","author":"Mehta-Shah","year":"2019","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.02.003_bib0039","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1182\/blood-2024-203577","article-title":"Duvelisib in Patients with Relapsed\/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial","volume":"144","author":"Mehta-Shah","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.02.003_bib0040","doi-asserted-by":"crossref","first-page":"TPS7593","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7593","article-title":"Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas","volume":"40","author":"Mehta-Shah","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2026.02.003_bib0041","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2022-168979","article-title":"Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas","volume":"140","author":"Haverkos","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.02.003_bib0042","first-page":"10","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","author":"Bennani","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.clml.2026.02.003_bib0043","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma","volume":"5","author":"Lemonnier","year":"2021","journal-title":"Blood Advances"},{"issue":"7","key":"10.1016\/j.clml.2026.02.003_bib0044","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma","volume":"22","author":"Kluin-Nelemans","year":"2011","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.clml.2026.02.003_bib0045","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"issue":"19","key":"10.1016\/j.clml.2026.02.003_bib0046","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1182\/bloodadvances.2023009767","article-title":"Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma","volume":"7","author":"Ruan","year":"2023","journal-title":"Blood Advances"},{"issue":"18","key":"10.1016\/j.clml.2026.02.003_bib0047","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/bloodadvances.2024014263","article-title":"Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma","volume":"9","author":"Khan","year":"2025","journal-title":"Blood Advances"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.02.003_bib0048","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.1182\/blood-2023-174109","article-title":"Phase II Trial of Duvelisib Maintenance after Autologous Stem Cell Transplant in T-Cell and B-Cell Non-Hodgkin Lymphomas: Results of Safety Lead in","volume":"142","author":"Saba","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.02.003_bib0049","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1182\/blood-2023-185543","article-title":"Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26)","volume":"142","author":"Jin","year":"2023","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2026.02.003_bib0050","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood.2023020912","article-title":"Peripheral T-cell lymphoma: are all patients high risk?","volume":"144","author":"Shea","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2026.02.003_bib0051","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.02.003_bib0052","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2026.02.003_bib0053","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2026.02.003_bib0054","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V106.11.811.811","article-title":"International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: Poor Outcome by Prognostic Indices and Lack of Efficacy with Anthracyclines","volume":"106","author":"Vose","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.02.003_bib0055","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.15258","article-title":"Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network","volume":"181","author":"Federico","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2026.02.003_bib0056","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdq359","article-title":"Comparison of four prognostic scores in peripheral T-cell lymphoma","volume":"22","author":"Guti\u00e9rrez-Garc\u00eda","year":"2011","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1016\/j.clml.2026.02.003_bib0057","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim","year":"2016","journal-title":"The Lancet Oncology"},{"issue":"13","key":"10.1016\/j.clml.2026.02.003_bib0058","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1158\/1078-0432.CCR-14-2195","article-title":"A New and Validated Clinical Prognostic Model (EPI) for Enteropathy-Associated T-cell Lymphoma","volume":"21","author":"de Baaij","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clml.2026.02.003_bib0059","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1095-0397(99)00016-3","article-title":"Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis","volume":"2","author":"Larson","year":"1999","journal-title":"Clin Positron Imaging"},{"issue":"4","key":"10.1016\/j.clml.2026.02.003_bib0060","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/annonc\/mdw011","article-title":"Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL)\u2020","volume":"27","author":"Cottereau","year":"2016","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1016\/j.clml.2026.02.003_bib0061","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2967\/jnumed.117.193946","article-title":"Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients","volume":"59","author":"Cottereau","year":"2018","journal-title":"Journal of Nuclear Medicine"},{"issue":"15","key":"10.1016\/j.clml.2026.02.003_bib0062","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1002\/cam4.3226","article-title":"Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma","volume":"9","author":"Kitadate","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2026.02.003_bib0063","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024015282","article-title":"Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma","author":"Iyer","year":"2025","journal-title":"Blood Advances"},{"issue":"12","key":"10.1016\/j.clml.2026.02.003_bib0064","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.clml.2026.02.003_bib0065","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1182\/bloodadvances.2023009953","article-title":"TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Advances"},{"issue":"9","key":"10.1016\/j.clml.2026.02.003_bib0066","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2026.02.003_bib0067","first-page":"4198","article-title":"Next-generation sequencing\u2013based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL","volume":"5","author":"Miljkovic","year":"2021","journal-title":"Blood Advances"},{"key":"10.1016\/j.clml.2026.02.003_bib0068","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1182\/blood-2021-148768","article-title":"End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas","volume":"138","author":"Mehta-Shah","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.02.003_bib0069","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1200\/JCO.2023.41.16_suppl.7563","article-title":"A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant","volume":"41","author":"Foley","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.02.003_bib0070","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2024-206518","article-title":"Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas","volume":"144","author":"Sugio","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.003_bib0071","first-page":"10","article-title":"Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking","author":"Cheng","year":"2021","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.clml.2026.02.003_bib0072","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:37:46Z","timestamp":1778067466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2152265026000388"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.02.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Optimizing Frontline Treatment for Peripheral T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}